drugset / Trial / NCT01049347

Amitriptyline and Paroxetine Treatment of Major Depression

NCT01049347

Phase 3 Completed 127 enrolled Central Institute of Mental Health, Mannheim
RandomizedParallel-groupTriple-blindTreatment

Summary

Activation of the hypothalamus-pituitary-adrenal system is monitored using saliva cortisol sampling during the antidepressant treatment with amitriptyline and paroxetine in moderately to severely depressed patients. Additionally, serum and plasma are sampled during the 5-week study period in order to study endocrine and metabolic parameters.

Timeline

Start
1997-10
Primary completion
2000-05
Completion
2000-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amitriptyline Small molecule 150 mg Oral
Comparator Paroxetine Small molecule 40 mg Oral